- Conditions
- Healthy
- Interventions
- PF-05230905
- Drug
- Lead sponsor
- Ablynx, a Sanofi company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2281–2304
of 11,389
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Single Muscle Fibers
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 65 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- DA-1241, Placebo, Sitagliptin
- Drug
- Lead sponsor
- Dong-A ST Co., Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Miami, Florida • High Point, North Carolina + 1 more
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Clear Cell Renal Cell Carcinoma
- Interventions
- Axitinib (VEGF-TKI), Cytoreductive Nephrectomy (CN), Metastasectomy (MET), Pembrolizumab
- Drug · Procedure · Biological
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- ziv-aflibercept
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
- Conditions
- Chronic Phase Chronic Myeloid Leukemia
- Interventions
- Nilotinib, Ruxolitinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
- Interventions
- BAL0891, Tislelizumab, Paclitaxel
- Drug · Combination Product
- Lead sponsor
- SillaJen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 11
- States / cities
- New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Fludarabine, Cyclophosphamide, Leukapheresis, Cytokine-induced killer cells, IL-2, ALT-803, Peripheral blood for correlative studies, Bone marrow for correlative studies
- Drug · Procedure · Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Epidural Placement
- Interventions
- Epidural Waveform Analysis
- Diagnostic Test
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Chemotherapy Induced Peripheral Neuropathy
- Interventions
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
- Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Coral Gables, Florida
- Conditions
- ACL Reconstruction
- Interventions
- Mental Skills Training (MST)
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 8 Years to 25 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Relapsed and Refractory Multiple Myeloma (RRMM)
- Interventions
- Non-Interventional
- Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Tarrytown, New York
- Conditions
- Relapsed/Refractory Solid Tumors/Hematological Malignancies
- Interventions
- Belinostat
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Whittier, California • Canton, Ohio
- Conditions
- Colorectal Cancer (Diagnosis)
- Interventions
- Not listed
- Lead sponsor
- Harbinger Health
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Leber Congenital Amaurosis, Inherited Retinal Diseases Caused by RPE65 Mutations
- Interventions
- HG004
- Drug
- Lead sponsor
- HuidaGene Therapeutics Co., Ltd.
- Industry
- Eligibility
- 6 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Sacramento, California • Houston, Texas
- Conditions
- Burn Injury
- Interventions
- SN514-066b
- Biological
- Lead sponsor
- SERDA bv
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Cancer, Tumor
- Interventions
- ARQ 197
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Cleveland, Ohio • Dallas, Texas
- Conditions
- Cervical Carcinoma
- Interventions
- LN-145, LN-145 + pembrolizumab
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 20 more
- Conditions
- Alzheimer's Disease
- Interventions
- Longeveron Mesenchymal Stem Cells, Placebo
- Biological
- Lead sponsor
- Longeveron Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Delray Beach, Florida • Miami, Florida
- Conditions
- Stage IV Lung Adenocarcinoma
- Interventions
- Certolizumab, cisplatin, pemetrexed
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
- Conditions
- Tinnitus, Noise Induced Tinnitus, Tinnitus, Subjective, Tinnitus, Objective, Tinnitus Aggravated, Tinnitus, Pulsatile, Tinnitus, Spontaneous Oto-Acoustic Emission, Tinnitus, Clicking, Tinnitus, Tensor Tympani Induced
- Interventions
- Meditation
- Behavioral
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Hypertension
- Interventions
- olmesartan medoxomil, placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 1 Year to 16 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
- Conditions
- Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma
- Interventions
- BMS-936564 (Anti-CXCR4)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 7 more
- Conditions
- COVID-19, Lymphocytopenia
- Interventions
- CYT107, Placebo
- Drug
- Lead sponsor
- Revimmune
- Industry
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas